米团
Lv2
130 积分
2022-09-05 加入
-
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
1个月前
已完结
-
Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer
1个月前
已完结
-
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
3个月前
已完结
-
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
3个月前
已完结
-
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
4个月前
已完结
-
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
6个月前
已完结
-
Global Stage Distribution of Breast Cancer at Diagnosis
7个月前
已完结
-
Global Stage Distribution of Breast Cancer at Diagnosis
7个月前
已完结
-
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
7个月前
已完结
-
Breast cancer
8个月前
已完结